Point B in the treatment of carcinoma cervix receives the dose of:
The question is asking about the dose received at Point B. The options aren't given, but the correct answer is likely related to the standard prescribed doses in brachytherapy. I think in the Manchester system, Point A is the primary target, and Point B is a secondary point. The dose to Point B is usually lower than Point A to avoid excessive toxicity. The standard dose for Point A is around 80-90 Gy in total, with Point B getting about 50-60 Gy.
Wait, but maybe it's in the context of a specific treatment protocol. For example, in HDR brachytherapy, the doses might be different. I need to be precise here. The question might be referencing the traditional Manchester system where Point B's dose is a fraction of Point A's. So if Point A is treated to 80 Gy, Point B would be around 50-60 Gy. The options might be in terms of a percentage or a specific number.
Looking at the correct answer provided, which is supposed to be the right choice, the explanation should confirm that Point B's dose is indeed lower than Point A's. The wrong options might include higher doses, which would risk complications, or maybe doses that are equal, which isn't correct.
I should also mention that Point B is used to assess the dose to the bladder and rectum, ensuring they aren't overexposed. The clinical pearl here is that Point B's dose is a fraction of Point A's to prevent toxicity. Also, the high-yield fact is that Point B is in the upper vaginal fornix and receives lower doses compared to Point A.
**Core Concept**
This question tests knowledge of radiation therapy dosimetry for cervical cancer, specifically the Manchester system. Point B is a reference point in the upper vaginal fornix used to assess dose distribution in brachytherapy. The goal is to deliver adequate tumor control while minimizing toxicity to surrounding organs.
**Why the Correct Answer is Right**
In the Manchester system, Point B receives a lower dose than Point A (80–90 Gy for Point A). The standard dose to Point B is **50–60 Gy** to avoid excessive toxicity to the bladder and rectum. This gradient ensures tumor control at the primary site (Point A) while protecting adjacent structures. The dose is calculated using low-dose-rate (LDR) brachytherapy protocols, with adjustments for high-dose-rate (HDR) techniques.
**Why Each Wrong Option is Incorrect**
**Option A:** Likely refers to a dose exceeding 80 Gy, which would risk severe late toxicity (e.g., rectal or bladder necrosis).
**Option B:** May suggest a dose equal to Point A, which is incorrect as Point B requires a lower dose.
**Option C:** Could indicate an overly low dose (<40 Gy), failing to achieve therapeutic effect at Point B.
**Option D:** Might imply a non-standard